Cilazapril
Based on 1 publication(s) in Google Scholar
Cilazapril is an orally active prodrug of the angiotensin-converting enzyme (ACE) inhibitor Cilazaprilat (HY-A0113). Cilazapril reduces plasma ACE activity. Cilazapril can be used in the research of hypertension (including essential and renal hypertension) and congestive heart failure.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 88768-40-5
- Fòrmula: C22H31N3O5
- Peso molecular:417.50
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Cilazapril
More
Actividad biológica
Descripciòn
In Vivo
Cilazapril (0.1-0.3 mg/kg orally) dose-dependently reduces plasma ACE activity and the pressor response to angiotensin in cats[1].
Cilazapril (10 mg/kg orally twice daily for 3.5 days) gradually reduces blood pressure in dogs with volume-depleted renal hypertension.
Cilazapril (10 mg/kg; p.o.; 2 weeks) decreases blood pressure, reduces heart weight to body weight ratio, and improves postischemic myocardial function in hyperthyroid rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 88768-40-5
-
Peso molecular 417.50
-
Fòrmula C22H31N3O5
-
SMILES
O=C([C@@H]1CCCN2N1C([C@@H](N[C@@H](CCC3=CC=CC=C3)C(OCC)=O)CCC2)=O)O
-
Synonyms
Ro 31-2848
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Pureza y Documentación
Referencias
[1]. Waterfall JF. A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor. Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):139S-150S. [Content Brief]
[2]. Asahi T, et al. Cilazapril prevents cardiac hypertrophy and postischemic myocardial dysfunction in hyperthyroid rats. Thyroid. 2001 Nov;11(11):1009-15. [Content Brief]
[3]. Bhutto IA, et al. Effects of cilazapril on the retinal vessels in spontaneously hypertensive rats: corrosion cast and scanning electron microscopic study. Life Sci. 1999;64(3):PL27-39. [Content Brief]
[4]. Szucs, T., Cilazapril. A review. Drugs, 1991. 41 Suppl 1: p. 18-24. [Content Brief]
[5]. Nussberger, J., et al., Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol, 1987. 9(1): p. 39-44. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Cilazapril Related Classifications
HY-A0043 Related Classifications
Powered by Bioz